Pemphigoid gestationis successfully treated with intravenous immunoglobulin

Almeida, Filipa Tavares; Sarabando, Rita; Pardal, Joana; Brito, Celeste

doi:10.1136/bcr-2018-224346

Cited by 6 publications

(3 citation statements)

References 14 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If PG remains refractory to treatment, or prolonged courses of steroids are required, other agents such as intravenous immunoglobulins, dapsone, and azathioprine < 2 mg/kg/day should be considered as steroid-sparing agents [65]. Intravenous immunoglobulins (FDA pregnancy category C) have a good safety profile for the patient and fetus and should be used either in monotherapy or as adjuvant treatment [66][67][68][69][70][71][72][73][74]. Dapsone (FDA pregnancy category C) is also considered safe during gestation.…”

Section: Treatmentmentioning

confidence: 99%

Pruritus in Pregnancy

et al. 2022

View full text Add to dashboard Cite

Pruritus in pregnancy is a common and burdensome symptom that may be a first sign of a pregnancy-specific pruritic disease (atopic eruption of pregnancy, polymorphic eruption of pregnancy, pemphigoid gestationis, and intrahepatic cholestasis in pregnancy) or a dermatosis coinciding with pregnancy by chance. Despite its high prevalence, pruritus is often underrated by physicians, and data regarding the safety profiles of drugs for pruritus are very limited. In this review, we illustrate the epidemiology, possible pathophysiology, clinical characteristics, and diagnostic workup of various pregnancy-related diseases and discuss antipruritic treatments. The prevalence of pruritus in pregnancy demonstrates the importance of symptom recognition and the need for an holistic approach, taking into account both the potential benefits for the patient and the potential risks to the fetus.

show abstract

Section: Treatmentmentioning

confidence: 99%

Pruritus in Pregnancy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Pemphigoid gestation (PG) is an autoimmune bullous disease that occurs during pregnancy or the puerperium[ 1 ]. The main clinical manifestations are tension blisters and bullae with urticaria-like plaques, accompanied by pruritus[ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnosis, fetal risk and treatment of pemphigoid gestationis in pregnancy: A case report

Jiao¹,

Ruan²,

Liu³

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Pemphigoid gestationis (PG) is a rare autoimmune blistering disease that usually presents in the second or third trimester, with an incidence of 1 per 50000 pregnancies. PG tends to recur with an earlier onset and a more severe course in subsequent pregnancies. Skin biopsy markers can be confirmed by direct immunofluorescence staining. CASE SUMMARY Our patient was diagnosed with PG at 8 mo of gestation with fresh bullous lesion marks on the abdomen and limbs. Termination of the pregnancy was performed by cesarean section at 37 + 4 wk of gestation. The patient delivered an infant weighing 3620 gm. The infant had urticaria-like and vesicular skin lesions and was diagnosed with PG. The patient was discharged on prednisolone and in a satisfactory condition. The infant was discharged after anti-inflammatory therapy for one week. CONCLUSION PG is a rarely reported disease, and 10% of newborns develop mild clinical symptoms consisting of urticaria-like or vesicular skin lesions. We intend to remind clinicians to consider this condition when a patient presents with such lesions so that treatment can be started early and neonatal morbidity can be taken into account.

show abstract

“…Other treatments include antihistamines, immunosuppressive drugs, plasmapheresis and intravenous immunoglobulins. [2][3][4][5] Dupilumab is a monoclonal antibody targeting the alpha subunit of the interleukin-4 (IL-4) receptor, inhibiting the IL-4 pathway of IL-13. This biotherapy has few side-effects, and its usefulness is increasingly being documented in refractory and corticosteroid-dependent bullous pemphigoid, in order to avoid the use of more potent immunosuppressant.…”

mentioning

confidence: 99%